OBJECTIVE: To assess the potential association of the functional polymorphism rs1801274 in the receptor IIa for the Fc portion of immunoglobin G (FcγRIIa) gene (FCGR2A-H131R) with the susceptibility to and the severity of community-acquired pneumonia (CAP). DESIGN: Multicenter prospective and observational study. SETTING: Four university hospitals in Spain. PATIENTS: FCGR2A-H131R polymorphism was determined in 1,262 patients with CAP and in 1,224 in the subject control group. MEASUREMENTS AND MAIN RESULTS: Severe sepsis was recorded in 366 patients. No significant differences in genotype or allele frequencies were seen among patients with CAP or pneumococcal CAP (PCAP) and controls. Patients with bacteremic PCAP (B-PCAP) had significantly higher frequencies of FCGR2A-H/H131 genotypes than those with nonbacteremic PCAP (p = .00016, odds ratio = 2.9, 95% confidence interval 1.58-5.3). The differences remained significant when adjusting for pneumonia severity index, hospital of origin, and intensive care unit admission (p = .0012, odds ratio = 2.83, 95% confidence interval 1.51-5.32). B-PCAP was associated with a significantly higher severity of the disease, evaluated as sepsis severity (p = .000007, odds ratio = 4.40, 95% confidence interval 2.31-8.39), multiorgan dysfunction syndrome (0.00048, odds ratio = 3.29, 95% confidence interval 1.69-6.41), intensive care unit admission, acute renal failure, and acute respiratory distress syndrome. CONCLUSIONS: Our results do not support a role of FCGR2A-H131R polymorphism in susceptibility to CAP or PCAP. However, we provide the insight that homozygosity for FCGR2A-H131 predisposes B-PCAP, which was associated with higher severity in our study.
OBJECTIVE: To assess the potential association of the functional polymorphism rs1801274 in the receptor IIa for the Fc portion of immunoglobin G (FcγRIIa) gene (FCGR2A-H131R) with the susceptibility to and the severity of community-acquired pneumonia (CAP). DESIGN: Multicenter prospective and observational study. SETTING: Four university hospitals in Spain. PATIENTS: FCGR2A-H131R polymorphism was determined in 1,262 patients with CAP and in 1,224 in the subject control group. MEASUREMENTS AND MAIN RESULTS: Severe sepsis was recorded in 366 patients. No significant differences in genotype or allele frequencies were seen among patients with CAP or pneumococcal CAP (PCAP) and controls. Patients with bacteremic PCAP (B-PCAP) had significantly higher frequencies of FCGR2A-H/H131 genotypes than those with nonbacteremic PCAP (p = .00016, odds ratio = 2.9, 95% confidence interval 1.58-5.3). The differences remained significant when adjusting for pneumonia severity index, hospital of origin, and intensive care unit admission (p = .0012, odds ratio = 2.83, 95% confidence interval 1.51-5.32). B-PCAP was associated with a significantly higher severity of the disease, evaluated as sepsis severity (p = .000007, odds ratio = 4.40, 95% confidence interval 2.31-8.39), multiorgan dysfunction syndrome (0.00048, odds ratio = 3.29, 95% confidence interval 1.69-6.41), intensive care unit admission, acute renal failure, and acute respiratory distress syndrome. CONCLUSIONS: Our results do not support a role of FCGR2A-H131R polymorphism in susceptibility to CAP or PCAP. However, we provide the insight that homozygosity for FCGR2A-H131 predisposes B-PCAP, which was associated with higher severity in our study.
Authors: Ignacio Martín-Loeches; Jordi Solé-Violán; Felipe Rodríguez de Castro; M Isabel García-Laorden; Luis Borderías; José Blanquer; Olga Rajas; M Luisa Briones; Javier Aspa; Estefanía Herrera-Ramos; José Alberto Marcos-Ramos; Ithaisa Sologuren; Nereida González-Quevedo; José María Ferrer-Agüero; Judith Noda; Carlos Rodríguez-Gallego Journal: Intensive Care Med Date: 2011-11-24 Impact factor: 17.440
Authors: Lyubov E Salnikova; Tamara V Smelaya; Arkadiy M Golubev; Alexander V Rubanovich; Viktor V Moroz Journal: Mol Biol Rep Date: 2013-09-26 Impact factor: 2.316
Authors: Halina M Trist; Peck Szee Tan; Bruce D Wines; Paul A Ramsland; Eva Orlowski; Janine Stubbs; Elizabeth E Gardiner; Geoffrey A Pietersz; Stephen J Kent; Ivan Stratov; Dennis R Burton; P Mark Hogarth Journal: J Immunol Date: 2013-12-16 Impact factor: 5.422
Authors: James D Chalmers; Gilly B Fleming; Julia Rutherford; Misao Matsushita; David C Kilpatrick; Adam T Hill Journal: Inflammation Date: 2014-10 Impact factor: 4.092
Authors: Marat V Khodoun; Zeynep Yesim Kucuk; Richard T Strait; Durga Krishnamurthy; Kevin Janek; Corey D Clay; Suzanne C Morris; Fred D Finkelman Journal: J Allergy Clin Immunol Date: 2013-10-18 Impact factor: 10.793